A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder

References

• Murray C, Lopez AD. Summary: the global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Geneva and Boston: World Health Organization and Harvard School of Public Health; 1996.
   Google Scholar
• Mancebo MC, Greenberg B, Grant JE, et al. Correlates of occupational disability in a clinical sample of obsessive-compulsive disorder. Compr Psychiatry. 2008;49(1):43–50.
   PubMed Web of Science ®Google Scholar
• Meier SM, Mattheisen M, Mors O, et al. Mortality among persons with obsessive-compulsive disorder in Denmark. JAMA psychiatry. 2016;73(3):268–274.
   PubMed Web of Science ®Google Scholar
• Ruscio A, Stein D, Chiu W, et al. The epidemiology of obsessive-compulsive disorder in the National comorbidity survey replication. Mol Psychiatry. 2010;15(1):53–63.
   PubMed Web of Science ®Google Scholar
• Heyman I, Mataix-Cols D, Fineberg N. Clinical review: obsessive-compulsive disorder. BMJ. 2006;333:424–429.
   PubMed Web of Science ®Google Scholar
• Skapinakis P, Caldwell DM, Hollingworth W, et al. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2016;3(8):730–739.
   PubMed Web of Science ®Google Scholar
• Treatment of Patients with Obsessive-Compulsive Disorder: American Psychiatric Association; 2007American psychiatric association practice guidelines. Available from: http://www.psychiatryonline.com/pracGuide/pracGuideChapToc_10.aspx
   Google Scholar
• NICE. Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. London National Institute for Health and Clinical Excellence (NICE); 2005 Available from: www.nice.org.uk/guidelines.aspx?o=guidelines.completed.
   Google Scholar
• Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive–compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol. 2007;17(2):79–93.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994;51(4):302–8.*.
   Google Scholar
• Masi G, Pfanner C, Brovedani P. Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study. J Psychiatr Res. 2013;47(8):1007–1012.
   PubMed Web of Science ®Google Scholar
• Murphy TK, Mutch PJ, Reid JM, et al. Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol. 2009;19(4):441–447.
   PubMed Web of Science ®Google Scholar
• Goodwin G, Fleischhacker W, Arango C, et al. Advantages and disadvantages of combination treatment with antipsychotics: ECNP consensus meeting, March 2008, Nice. Eur Neuropsychopharmacol. 2009;19(7):520–532.
   PubMed Web of Science ®Google Scholar
• Brakoulias V, Starcevic V, Belloch A, et al. International prescribing practices in Obsessive–Compulsive Disorder (OCD). Hum Psychopharmacology: Clin Exp. 2016;31(4):319–324.
   PubMed Web of Science ®Google Scholar
• Veale D, Miles S, Smallcombe N, et al. A typical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2014;14(1):317.
   PubMedGoogle Scholar
• Komossa K, Depping AM, Meyer M, et al. Second‐generation antipsychotics for obsessive compulsive disorder. Cochrane Lib. 2010;12.
   Google Scholar
• Üçok ALP, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 2008;7(1):58–62.
   PubMed Web of Science ®Google Scholar
• Bloch M, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622–632.
   PubMed Web of Science ®Google Scholar
• Erzegovesi S, Guglielmo E, Siliprandi F, et al. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2005;15(1):69–74.
   PubMed Web of Science ®Google Scholar
• Hollander E, Baldini Rossi N, Sood E, et al. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmcol. 2003;6(4):397–401.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57(8):794.
   PubMed Web of Science ®Google Scholar
• Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2011;31(2):174–179.
   PubMed Web of Science ®Google Scholar
• Sayyah M, Sayyah M, Boostani H, et al. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety. 2012;29(10):850–854.
   PubMed Web of Science ®Google Scholar
• Storch EA, Goddard AW, Grant JE, et al. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2013;74(6):e527–32.
   PubMed Web of Science ®Google Scholar
• Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry. 1995;56(9):423–429.
   PubMed Web of Science ®Google Scholar
• Angelucci F, Ricci V, Martinotti G, et al. Paliperidone for treatment of obsessive compulsive resistant symptoms in schizophrenia: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(7):1277–1278.
   PubMed Web of Science ®Google Scholar
• Connor KM, Payne VM, Gadde KM, et al. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005;66(1):49–51.
   PubMed Web of Science ®Google Scholar
• Simpson HB, Foa EB, Liebowitz MR, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013;70(11):1190–1199.
   PubMed Web of Science ®Google Scholar
• Foa EB, Simpson HB, Rosenfield D, et al. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder. J Clin Psychiatry. 2015;76(4):440–446.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57(8):794–801.
   PubMed Web of Science ®Google Scholar
• Hegde A, Kalyani BG, Arumugham SS, et al. Effectiveness of risperidone augmentation in Obsessive-Compulsive Disorder: experience from a specialty clinic in India. J Clin Psychopharmacol. 2016;36(4):381–384.
   PubMed Web of Science ®Google Scholar
• Arias Horcajadas F, Soto JA, Garcia-Cantalapiedra MJ, et al. [Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors]. Actas Esp Psiquiatr. 2006;34(3):147–152.
   PubMed Web of Science ®Google Scholar
• Li X, May RS, Tolbert LC, et al. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005;66(6):736–743.
   PubMed Web of Science ®Google Scholar
• Maina G, Pessina E, Albert U, et al. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2008;18(5):364–372.
   PubMed Web of Science ®Google Scholar
• Selvi Y, Atli A, Aydin A, et al. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Hum. 2011;26(1):51–57.
   Google Scholar
• Yoshimura R, Kaneko S, Shinkai K, et al. Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels. Psychiatry Clin Neurosci. 2006;60(3):389–393.
   PubMed Web of Science ®Google Scholar
• Buchsbaum MS, Hollander E, Pallanti S, et al. Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. Neuropsychobiology. 2006;53(3):157–168.
   PubMed Web of Science ®Google Scholar
• Scheltema BAA, Swets M, Machielsen M, et al. Outcome of psychosis I. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. J Clin Psychiatry. 2012;73(11):1395–1402.
   PubMed Web of Science ®Google Scholar
• Alevizos B, Lykouras L, Zervas IM, et al. Reply to risperidone-induced obsessive-compulsive symptoms: serotonin-dopamine imbalance? J Clin Psychopharmacol. 2004;24(5):549.
   PubMed Web of Science ®Google Scholar
• Duggal HS. Risperidone-induced obsessive-compulsive symptoms in two children. J Child Adolesc Psychopharmacol. 2004;14(1):155–156.
   PubMed Web of Science ®Google Scholar
• Ke CL, Yen CF, Chen CC, et al. Obsessive-compulsive symptoms associated with clozapine and risperidone treatment: three case reports and review of the literature. Kaohsiung J Med Sci. 2004;20(6):295–301.
   PubMedGoogle Scholar
• Marsanic VB, Aukst-Margetic B, Grgic N, et al. Misdiagnosis and exacerbation of unusual obsessive-compulsive disorder presentation with risperidone and clozapine in an adolescent girl - A case report. Coll Antropol. 2011;35(Suppl 1):293–296.
   PubMedGoogle Scholar
• Wang S-M, Han C, Lee S-J, et al. Paliperidone. Clin Drug Investig. 2012;32(8):497–512.
   PubMed Web of Science ®Google Scholar
• Vazquez-Bourgon J, Rodriguez-Rodriguez P, Gomez-Ruiz E, et al. Obsessive-compulsive symptoms induced by long-acting injectable paliperidone in a patient with schizophrenia: a case report. Ann Clin Psychiatry. 2014;26(4):301–302.
   PubMed Web of Science ®Google Scholar
• Kane JM, Fleischhacker WW, Hansen L, et al. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009;70(5):627.
   PubMed Web of Science ®Google Scholar
• Ak M, Bulut SD, Bozkurt A, et al. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study. Adv Ther. 2011;28(4):341–348.
   PubMed Web of Science ®Google Scholar
• Connor KM, Payne VM, Gadde KM, et al. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005;66(1):49–51.
   PubMed Web of Science ®Google Scholar
• Pessina E, Albert U, Bogetto F, et al. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol. 2009;24(5):265–269.
   PubMed Web of Science ®Google Scholar
• Glick ID, Poyurovsky M, Ivanova O, et al. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. J Clin Psychiatry. 2008;69(12):1856–1859.
   PubMed Web of Science ®Google Scholar
• Matsunaga H, Hayashida K, Maebayashi K, et al. A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder. Int. 2011;15(4):263–269.
   Web of Science ®Google Scholar
• Higuma H, Kanehisa M, Maruyama Y, et al. Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series. World J Biol Psychiatry. 2012;13(1):14–21.
   PubMed Web of Science ®Google Scholar
• Hou YC, Lai CH. Rapid responses of high-dose combined therapy of escitalopram and aripiprazole in a case of severe obsessive compulsive disorder with delusion. J Neuropsychiatry Clin Neurosci. 2014;26(2):E44–E45.
   PubMed Web of Science ®Google Scholar
• Ercan ES, Ardic UA, Ercan E, et al. A promising preliminary study of aripiprazole for treatment-resistant childhood Obsessive-Compulsive Disorder. J Child Adolesc Psychopharmacol. 2015;25(7):580–584.
   PubMed Web of Science ®Google Scholar
• Akca OF, Yilmaz S. Aripiprazole in the treatment of Obsessive Compulsive Disorder and aggressive behaviors in a child with prader willi syndrome: a case report. J Clin Psychopharmacol. 2016;36(5):526–528.
   PubMed Web of Science ®Google Scholar
• Patra S. Treat the disease not the symptoms: successful management of obsessive compulsive disorder in bipolar disorder with aripiprazole augmentation. Aust N Z J Psychiatry. 2016;50(8):809–810.
   PubMed Web of Science ®Google Scholar
• Hegde A, Kalyani BG, Arumugham SS, et al. Aripiprazole augmentation in highly treatment-resistant obsessive-compulsive disorder - experience from a specialty clinic in India. Int. 2017;21(1):67–9.
   Web of Science ®Google Scholar
• Shoja Shafti S, Kaviani H. Aripiprazole versus quetiapine in treatment-resistant obsessive–compulsive disorder: a double-blind clinical trial. Ther Advances Psychopharmacology. 2015;5(1):32–37.
   PubMed Web of Science ®Google Scholar
• Gupta P, Gupta R, Balhara YP. Obsessive-compulsive symptoms associated with aripiprazole treatment in bipolar disorder: a case report. J Clin Psychopharmacol. 2017;37(1):108–109.
   PubMed Web of Science ®Google Scholar
• Mouaffak F, Gallarda T, Bayle FJ, et al. Worsening of obsessive-compulsive symptoms after treatment with aripiprazole. J Clin Psychopharmacol. 2007;27(2):237–238.
   PubMed Web of Science ®Google Scholar
• Desarkar P, Das A, Nizamie SH. Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases. J Clin Psychopharmacol. 2007;27(3):305–306.
   PubMed Web of Science ®Google Scholar
• Takaki M. Aripiprazole as monotherapy at bedtime was effective for treatment of two cases of obsessive-compulsive disorder and insomnia. J Neuropsychiatry Clin Neurosci. 2014;26(3):E64.
   PubMed Web of Science ®Google Scholar
• Villari V, Frieri T, Fagiolini A. Aripiprazole augmentation in clozapine-associated obsessive-compulsive symptoms. J Clin Psychopharmacol. 2011;31(3):375–376.
   PubMed Web of Science ®Google Scholar
• Englisch S, Esslinger C, Inta D, et al. Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole. Clin Neuropharmacol. 2009;32(4):227–229.
   PubMed Web of Science ®Google Scholar
• Schonfelder S, Schirmbeck F, Waltereit R, et al. Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia. Clin Neuropharmacol. 2011;34(6):256–257.
   PubMed Web of Science ®Google Scholar
• Bloch M, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622.
   PubMed Web of Science ®Google Scholar
• Brakoulias V, Starcevic V, Belloch A, et al. Comorbidity, age of onset and suicidality in obsessive–compulsive disorder (OCD): an international collaboration. Compr Psychiatry. 2017;76:79–86.
   PubMed Web of Science ®Google Scholar
• Leckman JF, Denys D, Simpson HB, et al. Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V. Depress Anxiety. 2010;27(6):507–527.
   PubMed Web of Science ®Google Scholar
• Sobin C, Blundell ML, Weiller F, et al. Evidence of a schizotypy subtype in OCD. J Psychiatr Res. 2000;34(1):15–24.
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Faragian S, Pashinian A, et al. Clinical characteristics of schizotypal-related obsessive-compulsive disorder. Psychiatry Res. 2008;159(1–2):254–258.
   PubMed Web of Science ®Google Scholar
• Brakoulias V, Starcevic V, Berle D, et al. The clinical cH.haracteristics of obsessive compulsive disorder associated with high levels of schizotypy. Aust N Z J Psychiatry. 2014;48(9):852–860.
   PubMed Web of Science ®Google Scholar
• Brakoulias V, Starcevic V, Berle D, et al. Further support for five dimensions of obsessive-compulsive symptoms. J Nerv Ment Dis. 2013;201:452–459.
   PubMed Web of Science ®Google Scholar
• Bloch MH, Landeros-Weisenberger A, Rosario MC, et al. Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry. 2008;165(12):1532–1542.
   PubMed Web of Science ®Google Scholar
• Tukel R, Ertekin E, Batmaz S, et al. Influence of age of onset on clinical features in obsessive-compulsive disorder. Depress Anxiety. 2005;21(3):112–117.
   PubMed Web of Science ®Google Scholar
• Bottas A, Cooke RG, Richter MA. Comorbidity and pathophysiology of obsessive–compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia? J Psychiatry Neurosci. 2005;30(3):187.
   PubMed Web of Science ®Google Scholar
• de Mathis MA, do Rosario MC, Diniz JB, et al. Obsessive-compulsive disorder: influence of age at onset on comorbidity patterns. Eur Psychiatry: J Assoc Eur Psychiatrists. 2008;23(3):187–194.
   PubMed Web of Science ®Google Scholar
• Lochner C, Serebro P, der Merwe LV, et al. Comorbid obsessive–compulsive personality disorder in obsessive–compulsive disorder (OCD): A marker of severity. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1087–1092.
   PubMed Web of Science ®Google Scholar